Generic Medicine Info
Indications and Dosage
Adult: Initially, 2 mg wkly via deep IM inj. May nncrease according to patient's response. Maintainence: 1-10 mg wkly.
Comatose states, CNS depression, phaeochromocytoma.
Special Precautions
Hepatic impairment, renal impairment, CV disease, Parkinson's disease, epilepsy, depression, myasthenia gravis, prostatic hypertrophy, severe resp disease, blood dyscrasias and history of jaundice. Elderly. Pregnancy and lactation. Antipsychotics may precipitate coma due to their hepatotoxicity. Photosensitisation may occur in higher doses. May impair ability to drive and operate machines.
Adverse Reactions
Parkinsonian symptoms, dystonia, akathisia, tardive dyskinesia. Interference with temp regulation. Neuroleptic malignant syndrome. CNS effects, GI disturbances, nasal congestion, antimuscarinic symptoms, CV symptoms, ECG changes, endocrine effects, blood dyscrasias, photosensitisation, contact sensitisation and rashes, jaundice, corneal and lens opacities, purplish pigmentation of the skin, cornea, conjunctiva and retina.
Drug Interactions
ACE inhibitors, α-blockers, amantadine, general anaesthetics, angiotensin-II receptor antagonists, antiarrhythmics, tricyclic antidepressants, anxiolytics and hypnotics, apomorphine, artemether with lumefantrine, barbiturates, bromocriptine, cabergoline, calcium-channel blockers, carbamazepine, cimetidine, ethosuximide, levodopa, lisuride, memantine, methyldopa, metoclopramide, opioid analgesics, oxcarbazepine, pergolide, phenytoin, pramipexole, primidone, ritonavir, ropinirole, sibutramine, sympathomimetics, terfenadine, tetrabenazine, tramadol and valproate. Alcohol.
Mechanism of Action: Fluspirilene is a diphenylbutylpiperidine antipsychotic and has general properties similar to those of the phenothiazine, chlorpromazine. It is used in the treament of schizophrenia.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Fluspirilene from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in